Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.15M Buy
5,589,182
+1,667,706
+43% +$2.35M 0.03% 336
2026
Q1
$5.84M Buy
3,921,476
+1,081,992
+38% +$1.64M 0.03% 363
2025
Q4
$3.75M Sell
2,839,484
-414,476
-13% -$520K 0.02% 416
2025
Q3
$4.46M Buy
3,253,960
+1,358,068
+72% +$1.81M 0.02% 386
2025
Q2
$2.67M Sell
1,895,892
-118
-0% -$167 0.02% 452
2025
Q1
$3.01M Buy
+1,896,010
New +$4.62M 0.02% 425
2015
Q1
Sell
-670,000
Closed -$2.18M 646
2014
Q4
$2.18M Buy
+670,000
New +$1.85M 0.05% 349

Other funds holding GERN

Candriam SCA's GERN Position: Q2 2026 in Review

Candriam SCA increased its Geron (GERN) stake by 43% in Q2 2026, buying an estimated $2.35M and bringing the position to 5,589,182 shares worth $7.15M. The position accounts for 0.03% of the portfolio, ranked #336.

Candriam SCA first reported a position in GERN in Q4 2014 and has held it in 7 quarters since. 261 funds tracked by Wall St. Rank hold GERN as of Q2 2026.

  • Candriam SCA held 5,589,182 shares of Geron worth $7.15M as of Q2 2026.
  • Candriam SCA bought 1,667,706 Geron shares in Q2 2026, an estimated $2.35M.
  • Geron made up 0.03% of Candriam SCA's portfolio in Q2 2026, its #336 holding.
  • Candriam SCA first reported a position in Geron in Q4 2014 and has held it in 7 quarters since.
  • 261 funds tracked by Wall St. Rank held Geron as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.